NKTR Nektar Therapeutics Stock Quote

NKTR [NASD]

Index	-	P/E	-	EPS (ttm)	-2.62	Insider Own	1.20%	Shs Outstand	182.70M	Perf Week	-5.55%
Market Cap	2.96B	Forward P/E	-	EPS next Y	-2.18	Insider Trans	-7.15%	Shs Float	182.10M	Perf Month	-11.43%
Income	-474.30M	PEG	-	EPS next Q	-0.80	Inst Own	92.60%	Short Float	8.89%	Perf Quarter	0.68%
Sales	105.50M	P/S	28.09	EPS this Y	1.20%	Inst Trans	-0.00%	Short Ratio	18.94	Perf Half Y	-19.81%
Book/sh	4.95	P/B	3.30	EPS next Y	27.70%	ROA	-32.30%	Target Price	-	Perf Year	-4.83%
Cash/sh	5.52	P/C	2.96	EPS next 5Y	-7.30%	ROE	-45.70%	52W Range	12.92 - 26.75	Perf YTD	-3.82%
Dividend	-	P/FCF	-	EPS past 5Y	-32.40%	ROI	-39.50%	52W High	-38.88%	Beta	1.23
Dividend %	-	Quick Ratio	7.90	Sales past 5Y	-7.90%	Gross Margin	77.90%	52W Low	26.55%	ATR	0.67
Employees	718	Current Ratio	8.10	Sales Q/Q	-42.00%	Oper. Margin	-	RSI (14)	45.07	Volatility	3.41% 3.94%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-53.10%	Profit Margin	-	Rel Volume	0.48	Prev Close	16.56
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 05 AMC	Payout	-	Avg Volume	855.15K	Price	16.35
Recom	2.20	SMA20	-5.88%	SMA50	1.04%	SMA200	-10.57%	Volume	406,781	Change	-1.27%

Sep-10-21

Initiated

BofA Securities

Neutral

$18

Jun-28-21

Upgrade

Stifel

Hold → Buy

$22 → $24

May-18-21

Resumed

Goldman

Neutral

$24

Feb-22-21

Downgrade

The Benchmark Company

Buy → Hold

Jan-06-21

Initiated

Stifel

Hold

$18

Sep-14-20

Initiated

JP Morgan

Neutral

$26

Jun-10-20

Downgrade

CFRA

Hold → Sell

May-12-20

Reiterated

H.C. Wainwright

Neutral

$32 → $26

Apr-22-20

Initiated

The Benchmark Company

Buy

$26

Mar-30-20

Upgrade

Goldman

Sell → Neutral

$18 → $20

Mar-04-20

Initiated

Barclays

Overweight

$30

Feb-03-20

Upgrade

Mizuho

Neutral → Buy

$21 → $35

Oct-24-19

Initiated

Oppenheimer

Perform

$18

Oct-08-19

Downgrade

Goldman

Buy → Sell

$54 → $16

Aug-09-19

Downgrade

Mizuho

Buy → Neutral

$79 → $21

Aug-09-19

Downgrade

JP Morgan

Overweight → Neutral

$62 → $33

Aug-09-19

Downgrade

Jefferies

Buy → Hold

$59 → $23

Mar-15-19

Initiated

SVB Leerink

Mkt Perform

$38

Dec-13-18

Initiated

Goldman

Buy

$62

Jun-11-18

Downgrade

H.C. Wainwright

Buy → Neutral

$54

Sep-22-21 11:09AM	Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255 Zacks
Sep-21-21 11:02AM	Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study Benzinga +8.45%
09:00AM	Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study PR Newswire
Sep-13-21 11:47AM	Director Of Nektar Therapeutics Trades $544.92 Thousand In Company Stock Benzinga
Sep-02-21 12:03PM	Even after rising 9.3% this past week, Nektar Therapeutics (NASDAQ:NKTR) shareholders are still down 77% over the past three years Simply Wall St.
Aug-06-21 12:31PM	Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track Zacks
Aug-05-21 09:31PM	Nektar Therapeutics (NKTR) Q2 2021 Earnings Call Transcript Motley Fool
05:45PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Second Quarter 2021 Financial Results PR Newswire
Jul-29-21 03:05PM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Jul-27-21 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets PR Newswire
Jul-26-21 05:09PM	Were Hedge Funds Right About Nektar Therapeutics (NKTR)? Insider Monkey
Jul-19-21 09:00AM	Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer PR Newswire
Jun-07-21 08:30AM	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference PR Newswire
Jun-04-21 10:46AM	Should Shareholders Reconsider Nektar Therapeutics' (NASDAQ:NKTR) CEO Compensation Package? Simply Wall St.
May-27-21 06:36AM	We're Interested To See How Nektar Therapeutics (NASDAQ:NKTR) Uses Its Cash Hoard To Grow Simply Wall St.
May-20-21 11:00AM	Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity PR Newswire
May-18-21 08:00AM	Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) PR Newswire
May-10-21 03:09AM	Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last? Zacks
May-07-21 03:30AM	Nektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript Motley Fool +8.53%
May-06-21 05:45PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports First Quarter 2021 Financial Results PR Newswire
Apr-29-21 12:34PM	Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline Zacks
Apr-27-21 06:00PM	Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets PR Newswire
Mar-27-21 11:31AM	Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound? Zacks
Feb-26-21 09:09AM	Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track Zacks
07:20AM	Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2021 Simply Wall St.
03:11AM	Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues SmarterAnalyst
01:01AM	Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript Motley Fool
Feb-25-21 05:10PM	Nektar Therapeutics: Q4 Earnings Insights Benzinga
03:15PM	Nektar Therapeutics to Host Earnings Call ACCESSWIRE
Feb-18-21 05:30PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets PR Newswire
Feb-17-21 04:19PM	Nektar Therapeutics Breaks Out On Combo Study With Merck's Keytruda Investor's Business Daily +13.36%
09:25AM	Nektar Therapeutics Secures $150M From SFJ Pharma For New Study With BEMPEG/Pembrolizumab Combo In Head & Neck Cancer Benzinga
08:00AM	Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) PR Newswire
07:59AM	Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer PR Newswire
Feb-08-21 07:19AM	Investors Who Bought Nektar Therapeutics (NASDAQ:NKTR) Shares Five Years Ago Are Now Up 75% Simply Wall St.
Jan-24-21 06:08AM	3 Stocks Wall Street Thinks Will Soar 50% or More in 2021 Motley Fool
Jan-06-21 05:00PM	Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference PR Newswire
07:30AM	The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping Benzinga
Jan-05-21 04:20PM	Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development PR Newswire
Dec-22-20 11:03AM	Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options Zacks
08:30AM	Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million PR Newswire
Dec-18-20 08:15PM	Is NKTR A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-16-20 10:45AM	Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers Zacks
Dec-15-20 08:30AM	Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer PR Newswire
Dec-08-20 06:00AM	SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of EQT, ZYNE, NKTR, and FMO; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Dec-07-20 04:00PM	Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting PR Newswire
Dec-05-20 11:32AM	Why Is Nektar (NKTR) Up 3% Since Last Earnings Report? Zacks
Nov-11-20 02:00PM	Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
Nov-10-20 06:47AM	Nektar Therapeutics (NASDAQ:NKTR) Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St.
Nov-09-20 09:04AM	Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat Zacks
Nov-06-20 02:01AM	Nektar Therapeutics (NKTR) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 08:00PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Third Quarter 2020 Financial Results PR Newswire
04:00PM	Nektar Therapeutics to Host Earnings Call ACCESSWIRE
Nov-04-20 10:15AM	New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress PR Newswire +7.61%
Oct-29-20 06:00PM	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress PR Newswire
12:34PM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-20 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets PR Newswire
12:32PM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-27-20 07:30AM	Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19 PR Newswire
Oct-05-20 03:27PM	We Think Nektar Therapeutics (NASDAQ:NKTR) Can Afford To Drive Business Growth Simply Wall St. +6.14%
Sep-28-20 05:24PM	Hedge Funds Are Coming Back To Nektar Therapeutics (NKTR) Insider Monkey
Sep-24-20 06:47PM	Analyst Report: Nektar Therapeutics CoinDesk
Sep-05-20 11:32AM	Nektar (NKTR) Down 12% Since Last Earnings Report: Can It Rebound? Zacks
Aug-12-20 09:42AM	Did Hedge Funds Make The Right Call On Nektar Therapeutics (NKTR) ? Insider Monkey
08:00AM	Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck PR Newswire
Aug-07-20 11:35AM	Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress Zacks
Aug-06-20 07:00PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Second Quarter 2020 Financial Results PR Newswire
Aug-05-20 11:15AM	If You Had Bought Nektar Therapeutics (NASDAQ:NKTR) Stock Five Years Ago, You Could Pocket A 106% Gain Today Simply Wall St.
Jul-30-20 12:33PM	Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline Zacks
Jul-28-20 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets PR Newswire
Jun-23-20 09:46PM	Hedge Funds Arent Impressed By Nektar Therapeutics (NKTR) Insider Monkey
Jun-14-20 09:25PM	Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
Jun-06-20 11:31AM	Why Is Nektar (NKTR) Up 12% Since Last Earnings Report? Zacks
Jun-04-20 05:00PM	Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020) PR Newswire
May-29-20 05:00PM	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020) PR Newswire
May-26-20 11:11AM	7 Stocks Maverick Capital Continues to Buy GuruFocus.com
May-22-20 08:30AM	Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal PR Newswire
May-18-20 08:05AM	Is There An Opportunity With Nektar Therapeutics's (NASDAQ:NKTR) 46% Undervaluation? Simply Wall St.
May-17-20 07:13PM	Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics Investing.com
May-12-20 06:27AM	H.C. Wainwright Sticks to Their Hold Rating for Nektar Therapeutics Investing.com
May-08-20 10:29AM	Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates Zacks
03:57AM	No Surprises in Nektar's Q1; COVID-19 Likely Just a Small Bump in Road for Bempeg Trials Morningstar
03:31AM	Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 05:55PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports First Quarter 2020 Financial Results PR Newswire
Apr-30-20 12:33PM	Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline Zacks
Apr-28-20 05:00PM	Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets PR Newswire
Apr-09-20 06:08PM	Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals
Apr-06-20 06:24AM	Need To Know: Analysts Are Much More Bullish On Nektar Therapeutics (NASDAQ:NKTR) Revenues Simply Wall St. +7.12%
Mar-29-20 10:51PM	Hedge Funds Are Betting On Nektar Therapeutics (NKTR) Insider Monkey
Mar-28-20 11:30AM	Why Is Nektar (NKTR) Down 16.1% Since Last Earnings Report? Zacks
Mar-11-20 09:19PM	Edited Transcript of NKTR earnings conference call or presentation 27-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -8.40%
Mar-01-20 09:15AM	Nektar Therapeutics Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Feb-28-20 06:30PM	Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference PR Newswire
08:15AM	Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up Zacks
04:39AM	Business as Usual for No-Moat Nektar; Bempeg's Phase Three Trials With Bristol to See 2021 Readouts Morningstar

Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Curet Myriam	Director	Sep 22	Sale	17.78	3,665	65,164	25,775	Sep 24 06:14 PM
CHESS ROBERT	Director	Sep 22	Sale	17.94	4,600	82,524	279,873	Sep 24 06:13 PM
Ajer Jeffrey Robert	Director	Sep 22	Sale	17.78	3,665	65,164	32,510	Sep 24 06:12 PM
WHITFIELD ROY A	Director	Sep 16	Option Exercise	13.80	40,000	552,000	225,850	Sep 17 06:44 PM
CHESS ROBERT	Director	Sep 09	Option Exercise	13.80	10,279	141,850	284,552	Sep 10 06:03 PM
CHESS ROBERT	Director	Sep 09	Sale	16.02	10,279	164,670	274,273	Sep 10 06:03 PM
CHESS ROBERT	Director	Sep 08	Option Exercise	13.80	8,000	110,400	282,273	Sep 10 06:03 PM
CHESS ROBERT	Director	Sep 08	Sale	16.00	8,000	128,000	274,273	Sep 10 06:03 PM
GREER R SCOTT	Director	Aug 31	Option Exercise	12.70	45,000	571,500	270,674	Aug 31 06:26 PM
Labrucherie Gil M	SVP, COO & CFO	Aug 17	Sale	13.56	3,000	40,680	240,231	Aug 18 06:58 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 16	Sale	13.83	7,662	105,965	212,803	Aug 18 07:04 PM
Wilson Mark Andrew	SVP & General Counsel	Aug 16	Sale	13.83	1,910	26,415	72,900	Aug 18 07:02 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Aug 16	Sale	13.83	13,339	184,478	137,822	Aug 18 07:00 PM
ROBIN HOWARD W	President & CEO	Aug 16	Sale	13.83	11,515	159,252	424,123	Aug 18 07:01 PM
NORTHCOTT JOHN	SVP & Chief Commercial Officer	Aug 16	Sale	13.83	6,192	85,635	200,915	Aug 18 06:59 PM
Labrucherie Gil M	SVP, COO & CFO	Aug 16	Sale	13.83	7,867	108,801	243,231	Aug 18 06:58 PM
CHESS ROBERT	Director	Jul 22	Option Exercise	13.80	91	1,256	280,664	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 22	Sale	16.80	91	1,529	280,573	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 21	Option Exercise	13.80	3,524	48,631	284,097	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 21	Sale	16.81	3,524	59,238	280,573	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 20	Option Exercise	13.80	2,106	29,063	282,679	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 20	Sale	16.80	2,106	35,381	280,573	Jul 22 07:13 PM
Wilson Mark Andrew	SVP & General Counsel	May 17	Sale	18.30	1,917	35,081	74,810	May 19 07:07 PM
Zalevsky Jonathan	Chief R&D Officer	May 17	Sale	18.30	31,111	569,331	235,065	May 19 07:08 PM
ROBIN HOWARD W	President & CEO	May 17	Sale	18.30	11,560	211,548	435,638	May 19 07:05 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	May 17	Sale	18.30	13,391	245,055	151,161	May 19 07:06 PM
Labrucherie Gil M	SVP, COO & CFO	May 17	Sale	18.30	7,898	144,533	251,098	May 19 07:04 PM
NORTHCOTT JOHN	SVP & Chief Commercial Officer	May 17	Sale	18.30	6,085	111,356	207,107	May 19 07:04 PM
CHESS ROBERT	Director	May 12	Option Exercise	13.80	8,000	110,400	288,573	May 14 06:05 PM
CHESS ROBERT	Director	May 12	Sale	19.34	8,000	154,720	280,573	May 14 06:05 PM
CHESS ROBERT	Director	Apr 14	Option Exercise	13.80	8,000	110,400	288,573	Apr 16 06:02 PM
CHESS ROBERT	Director	Apr 14	Sale	18.98	8,000	151,840	280,573	Apr 16 06:02 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 16	Sale	22.37	24,141	540,034	266,176	Feb 18 07:07 PM
Wilson Mark Andrew	SVP & General Counsel	Feb 16	Sale	22.37	2,173	48,610	76,727	Feb 18 07:06 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Feb 16	Sale	22.37	11,705	261,841	164,552	Feb 18 07:05 PM
NORTHCOTT JOHN	SVP & Chief Commercial Officer	Feb 16	Sale	22.37	15,358	343,558	213,192	Feb 18 07:03 PM
ROBIN HOWARD W	President & CEO	Feb 16	Sale	22.37	11,495	257,143	447,198	Feb 18 07:04 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 16	Sale	22.37	7,977	178,445	258,996	Feb 18 07:03 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 04	Option Exercise	8.80	50,000	440,000	316,973	Feb 04 08:42 PM
ROBIN HOWARD W	President & CEO	Feb 04	Option Exercise	8.80	150,000	1,320,000	608,693	Feb 04 08:43 PM
ROBIN HOWARD W	President & CEO	Feb 04	Sale	20.29	150,000	3,042,906	458,693	Feb 04 08:43 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 04	Sale	19.81	50,000	990,500	266,973	Feb 04 08:42 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 03	Option Exercise	8.80	50,000	440,000	316,973	Feb 04 08:42 PM
ROBIN HOWARD W	President & CEO	Feb 03	Option Exercise	8.80	150,000	1,320,000	608,693	Feb 04 08:43 PM
Wilson Mark Andrew	SVP & General Counsel	Feb 03	Sale	19.45	5,344	103,941	78,900	Feb 04 08:44 PM
ROBIN HOWARD W	President & CEO	Feb 03	Sale	19.72	150,000	2,958,000	458,693	Feb 04 08:43 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 03	Sale	19.61	50,000	980,500	266,973	Feb 04 08:42 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 02	Option Exercise	8.80	50,000	440,000	316,973	Feb 04 08:42 PM
ROBIN HOWARD W	President & CEO	Feb 02	Option Exercise	8.80	150,000	1,320,000	608,693	Feb 04 08:43 PM
ROBIN HOWARD W	President & CEO	Feb 02	Sale	19.77	150,000	2,966,025	458,693	Feb 04 08:43 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 02	Sale	20.17	50,000	1,008,629	266,973	Feb 04 08:42 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Jan 28	Option Exercise	8.80	75,000	660,000	251,257	Jan 29 06:10 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Jan 28	Sale	18.62	75,000	1,396,500	176,257	Jan 29 06:10 PM
GREER R SCOTT	Director	Jan 05	Option Exercise	13.80	40,000	552,000	225,674	Jan 05 05:09 PM
Myriam Curet	Director	Dec 15	Sale	17.82	1,560	27,799	19,240	Dec 17 06:08 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 23	Sale	16.40	16,380	268,632	250,317	Nov 25 06:09 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 16	Sale	16.93	29,618	501,433	266,697	Nov 18 07:08 PM
Wilson Mark Andrew	SVP & General Counsel	Nov 16	Sale	16.93	1,539	26,055	49,850	Nov 18 07:07 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Nov 16	Sale	16.93	11,976	202,754	159,757	Nov 18 07:05 PM
ROBIN HOWARD W	President & CEO	Nov 16	Sale	16.93	11,975	202,737	352,043	Nov 18 07:04 PM
Labrucherie Gil M	SVP, COO & CFO	Nov 16	Sale	16.93	8,276	140,113	226,973	Nov 18 07:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience